Enhanced alpha-synuclein expression in human neurodegenerative diseases: pathogenetic and therapeutic implications.

Enhanced alpha-synuclein expression in human neurodegenerative diseases: pathogenetic and therapeutic implications.

Item
http://www.wikidata.org/entity/Q37524138
Generation of SNCA Cell Models Using Zinc Finger Nuclease (ZFN) Technology for Efficient High-Throughput Drug ScreeningSerine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo.A novel "molecular tweezer" inhibitor of α-synuclein neurotoxicity in vitro and in vivo.Neurodegenerative processes in Huntington's disease.Head injury, α-synuclein Rep1, and Parkinson's disease.Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression.Intrinsically disordered proteins: from sequence and conformational properties toward drug discovery.Targeting the chameleon: a focused look at α-synuclein and its roles in neurodegeneration.Using NMR chemical shifts to calculate the propensity for structural order and disorder in proteins.Pore-Forming Proteins as Mediators of Novel Epigenetic Mechanism of Epilepsy.Inclusion of a portion of the native SNCA 3'UTR reduces toxicity of human S129A SNCA on striatal-projecting dopamine neurons in rat substantia nigra.Melatonin attenuates kainic acid-induced neurotoxicity in mouse hippocampus via inhibition of autophagy and α-synuclein aggregation.Alpha-synuclein induces the unfolded protein response in Parkinson's disease SNCA triplication iPSC-derived neurons.Melatonin reduces the expression of alpha-synuclein in the dopamine containing neuronal regions of amphetamine-treated postnatal rats.Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson's disease.
P2860

Enhanced alpha-synuclein expression in human neurodegenerative diseases: pathogenetic and therapeutic implications.

Item
http://www.wikidata.org/entity/Q37524138
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Enhanced alpha-synuclein expre ...... and therapeutic implications.
@en
Enhanced alpha-synuclein expre ...... and therapeutic implications.
@nl
type
label
Enhanced alpha-synuclein expre ...... and therapeutic implications.
@en
Enhanced alpha-synuclein expre ...... and therapeutic implications.
@nl
prefLabel
Enhanced alpha-synuclein expre ...... and therapeutic implications.
@en
Enhanced alpha-synuclein expre ...... and therapeutic implications.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Enhanced alpha-synuclein expre ...... c and therapeutic implications
@en
P2093
P304
P31
P356
10.2174/138920309789351912
P433
P478
P50
P577
P698
P921